Pharma channel feed

'A done deal': FDA ad­vi­so­ry com­mit­tee votes unan­i­mous­ly against ef­fi­ca­cy da­ta for OTC nasal de­con­ges­tant

Last year
FDA+

FDA slaps CVS, Wal­greens and oth­ers with warn­ing let­ters for un­ap­proved eye treat­ments

Last year
FDA+

As­traZeneca, Am­gen de­but new Tezspire mar­ket­ing dur­ing Sep­tem­ber asth­ma ‘peak week’

Last year
Marketing

Mar­ket­ingRx roundup: Bris­tol My­ers re-ups cross coun­try cy­cling fundrais­er; Pfiz­er em­ploy­ees share mi­graine ‘per­sonas’

Last year
Marketing

WCLC roundup: As­traZeneca, Am­gen, J&J and Hutchmed tout new com­bi­na­tion or con­fir­ma­to­ry da­ta

Last year
R&D

Bi­o­Lin­eRx’s Aphex­da ap­proved to aid stem cell trans­plants for mul­ti­ple myelo­ma pa­tients

Last year
FDA+

As­traZeneca ad­dress­es re­port that CEO Pas­cal So­ri­ot plans to de­part

Last year
People

Om­ni­com Health agency Har­ri­son and Star goes back to sci­ence roots with new lead­ers and new pur­pose

Last year
Marketing

DOJ and Dan­co Lab­o­ra­to­ries pe­ti­tion Supreme Court over mifepri­s­tone re­stric­tions

Last year
Law

San­doz and Sam­sung Bioepis ink com­mer­cial­iza­tion agree­ment for Ste­lara biosim­i­lar

Last year

FDA green­lights up­dat­ed Covid shots, mak­ing fall boost­er roll­out im­mi­nent

Last year
FDA+

Roche CEO out­lines new R&D strat­e­gy af­ter years of late-stage tri­al fail­ures

Last year
R&D

Kroger inks $1.4B set­tle­ment deal for opi­oid law­suits

Last year
Law

New bi­par­ti­san House bill in­cludes ma­jor PBM re­forms

Last year
Law

FDA main­tains Covid flex­i­bil­i­ties for IRB re­view of ex­pand­ed ac­cess drugs for in­di­vid­u­als

Last year
FDA+

Citius Phar­ma­ceu­ti­cals looks to re­file for­mer Ei­sai can­cer drug in ear­ly 2024

Last year
FDA+

Medicare en­rollees paid far more for drugs than plan spon­sors did in 2021, GAO says

Last year
FDA+

No­var­tis ad­justs busi­ness unit names in prepa­ra­tion for San­doz gener­ics and biosim­i­lars spin­off

Last year
Marketing

CDC en­cour­ages fall flu vac­ci­na­tions to tame symp­tom sever­i­ty in ‘Wild to Mild’ cam­paign

Last year
Marketing

MIT sci­en­tists look to un­lock po­ten­tial of ‘self-ad­ju­vant­i­ng’ mR­NA vac­cines in mice

Last year
R&D

Can No­vo Nordisk's block­buster weight loss drug and oth­er GLP-1s al­so work in NASH? The an­swer is com­pli­cat­ed

Last year
R&D
In Focus

Mer­ck to face FDA ad­comm in No­vem­ber over pre­vi­ous­ly re­ject­ed po­ten­tial chron­ic cough drug

Last year
FDA+

Bris­tol My­ers Squibb and Cel­gene named in class ac­tion suit over can­cer block­buster Po­m­a­lyst

Last year
Law

IPG Health de­buts new clin­i­cal tri­al di­ver­si­ty ap­proach based on ex­pe­ri­ence and spurred by phar­ma re­quests

Last year
Marketing
First page Previous page 101102103104105106107 Next page Last page
A service from the Financial Times